Cybin

Cybin

Cybin was founded in 2019 by a group of biotech entrepreneurs and operators and is led by CEO Doug Drysdale. Headquartered in Toronto, the company pursued a public listing in 2020 to fund the development of regulated psychedelic-based therapies. The firm's work centers on major depressive disorder, anxiety disorders, and alcohol use disorder — conditions where standard pharmacotherapy has seen limited innovation over the past two decades. Cybin operates as a clinical-stage biopharmaceutical company rather than a traditional asset manager. Its strategy combines proprietary deuterated tryptamine compounds with a structured drug-development pipeline. The lead program, CYB003, is a deuterated psilocybin analog evaluated in a Phase 2 trial for major depressive disorder. A second program, CYB004, explores a deuterated DMT formulation for generalized anxiety disorder. The firm also runs EMBARK, a psychological support framework designed to accompany psychedelic administration in clinical settings. Geographic activity spans Canada and the United States, where the FDA has granted Breakthrough Therapy Designation to CYB003. In January 2024, Cybin announced it had completed dosing in its Phase 2 study of CYB003 for major depressive disorder. The company has expanded through acquisitions, including the 2021 purchase of Adelia Therapeutics, which brought in additional intellectual property and preclinical programs. Cybin has established partnerships with academic institutions and clinical research organizations to execute its trials. In late 2023, the firm upsized a public offering to raise approximately $135 million in gross proceeds. Managed by a lean, biotech-experienced team including former senior leadership from the pharmaceutical industry, Cybin remains structured as a pure-play public issuer. The firm also maintains a dealer's license through its Shoppers Drug Mart supply agreement in Canada for medical psilocybin access. Cybin's structural differentiator lies in its deuterated chemistry approach, which aims to improve upon classic psychedelics by altering metabolic stability and side-effect profiles. Unlike non-profit research initiatives or cash-burning private startups, Cybin operates as a listed, capital-markets-facing entity subject to quarterly disclosure and public accountability. This hybrid of clinical-stage drug development and public-market financing creates a governance model distinct from both venture-backed biotech and academic psychedelic research.